Ascites is frequently seen in patients suffering with ovarian cancer. Paracentesis is a well-established method to provide symptomatic relief. Systemic adverse effects have occurred in paracentesis for ascites arising from other conditions. However, malignancy-related ascites has a different pathophysiology than nonmalignant ascites and as such the concerns related to the latter condition may not apply in patients with ovarian cancer. This study has shown that paracentesis is both effective and safe as an outpatient procedure for managing malignancy-related ascites.
Get full access to this article
View all access options for this article.
References
1.
BergmanF. Carcinoma of the ovary. A clinicopathological study of 86 autopsy cases with special reference to mode of spread. Acta Obstet Gynecol Scand, 1966; 45:211–231.
2.
LifshitzS. Ascites, pathophysiology and control measures. Int J Radiat Oncol Biol Phys, 1982; 8:1423–1426.
3.
PulsLE, DunihoT, HunterJE, KryscioR, BlackhurstD, GallionH. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol, 1996; 61:109–121.
4.
HirabayashiK, GrahamJ. Genesis of ascites in ovarian cancer. Am J Obstet Gynecol, 1970; 106:492–497.
5.
FeldmanGB, KnappRC, OrderSE, HellmanS. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res, 1972; 32:1663–1666.
6.
DvorakHF, BrownLF, DetmarM, DvorakAM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 1995; 146:1029–1039.
7.
BelottiD, PaganoniP, ManentiL, GarofaloA, MarchiniS, TarabolettiG, GiavazziR. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian cancer cells: Implications for ascites formation. Cancer Res, 2003; 63:5224–5229.
8.
ManentiL, PaganoniP, FlorianiI, LandoniF, TorriV, BudaA, TarabolettiG, LabiancaR, BelottiD, GiavazziG. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer, 2003; 39:1948–1956.
9.
GravesLE, AriztiaEV, NavariJR, MatzelHJ, StackMS, FishmanDA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res, 2004; 64:7045–7049.
10.
DulucD, CorvaisierM, BlanchardS, CatalaL, DescampsP, GamelinE, PonsodaS, DelnesteY, HebbarM, JeanninP. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer, 2009; 125:367–373.
11.
LevequeL, DeknuydtF, BioleyG, OldLJ, MatsuzakiJ, OdunsiK, AyyoubM, ValmoriD. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J Immunother, 2009; 32:101–108.
12.
CampbellMS, BrensingerCM, SanyalAJ, GenningsC, WongF, KowdleyKV, McCashlandT, ReddyKR. Quality of life in refractory ascites: Transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology, 2005; 42:635–640.
13.
EassonAM, BezjakA, RossS, WrightJG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol, 2007; 14:2348–2357.
14.
WangSS, LuCW, ChaoY, LeeFY, ChenTW, LinHC, LeeSD, TsaiYT, LoKJ. Total paracentesis in non-alcoholic cirrhotics with massive ascites: Mid-term effects on systemic and hepatic haemodynamics and renal function. J Gastroenterol Hepatol, 1994; 9:592–596.
15.
Ruiz-del-ArbolL, MonescilloA, JimenezW, Garcia-PlazaA, ArroyoV, RodesJ. Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology, 1997; 113:579–586.
16.
CollS, VilaMC, MolinaL, GimenezMD, GuarnerC, SolaR. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: Influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol, 2004; 16:347–353.
17.
LeeCW, BociekG, FaughtW. A survey of practice in management of malignant ascites. J Pain Symptom Manage, 1998; 16:96–101.
18.
MacdonaldR, KirwanJ, RobertsS, GrayD, AllsoppL, GreenJ. Ovarian cancer, ascites: A questionnaire on current management in the United Kingdom. J Palliat Med, 2006; 9:1264–1270.
19.
McNamaraP. Paracentesis—An effective method of symptom control in the palliative care setting?Palliat Med, 2000; 14:62–64.
20.
StephensonJ, GilbertJ. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med, 2002; 16:213–218.
